AstraZeneca earnings q3 2018


“Every single new product we’ve launched is doing very well,” he added. Shares of the company were up 1.8 percent on Thursday morning.

Total revenue, however, fell 14 percent in dollar terms to $5.34 billion and core earnings per share, which exclude some items, were down 37 percent to 71 cents, reflecting lower income from divestments and investment behind new drug launches.

Analysts, on average, had forecast earnings of 72 cents on revenue of $5.30 billion, Refinitiv data showed. For the full year, the company kept its financial guidance unchanged.

Source link

Products You May Like

Articles You May Like

Small banks you’ve never heard of quietly power the booming fintech industry
Stocks making the biggest moves midday: XPO Logistics, Nvidia, Canopy
Want a raise? These five things could net you more cash
Tom Ridge at center of questions over JetSmarter’s security screening
Mattel has worst day in 20 years after undercutting estimates

Leave a Reply

Your email address will not be published. Required fields are marked *